IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v41y1997isup1ps71-s89.html

Pharmaceutical cost containment and innovation in the United States

Author

Listed:
  • Kane, Nancy M.

Abstract

No abstract is available for this item.

Suggested Citation

  • Kane, Nancy M., 1997. "Pharmaceutical cost containment and innovation in the United States," Health Policy, Elsevier, vol. 41(Supplemen), pages 71-89, September.
    • Handle: RePEc:eee:hepoli:v:41:y:1997:i:sup1:p:s71-s89
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(97)00048-1
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to

    for a different version of it.

    References listed on IDEAS

    as
    1. Comanor, William S, 1986. "The Political Economy of the Pharmaceutical Industry," Journal of Economic Literature, American Economic Association, vol. 24(3), pages 1178-1217, September.
    2. F. M. Scherer, 1993. "Pricing, Profits, and Technological Progress in the Pharmaceutical Industry," Journal of Economic Perspectives, American Economic Association, vol. 7(3), pages 97-115, Summer.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Gregory S. Zaric & Bernie J. O'Brien, 2005. "Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget," Health Economics, John Wiley & Sons, Ltd., vol. 14(8), pages 793-803, August.
    2. Adriana Benítez-Rico & Arizbeth Pérez-Martínez & Bryan Isaac Muñóz-López & Laura Martino-Roaro & Jorge Adan Alegría-Baños & Arely Vergara-Castañeda & Alejandro Islas-García, 2023. "Medical Household Waste as a Potential Environmental Hazard: An Ecological and Epidemiological Approach," IJERPH, MDPI, vol. 20(7), pages 1-18, April.
    3. Donald Vandegrift & Anusua Datta, 2006. "Prescription Drug Expenditures in the United States: The Effects of Obesity, Demographics, and New Pharmaceutical Products," Southern Economic Journal, John Wiley & Sons, vol. 73(2), pages 515-529, October.
    4. Schneeweiss, Sebastian & Schoffski, Oliver & Selke, Gisbert W, 1998. "What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?," Health Policy, Elsevier, vol. 44(3), pages 253-260, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Regan, Tracy L., 2008. "Generic entry, price competition, and market segmentation in the prescription drug market," International Journal of Industrial Organization, Elsevier, vol. 26(4), pages 930-948, July.
    2. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
    3. Tapon, Francis & Cadsby, Charles Bram, 1996. "The optimal organization of research: evidence from eight case studies of pharmaceutical firms," Journal of Economic Behavior & Organization, Elsevier, vol. 31(3), pages 381-399, December.
    4. Wogart, Jan Peter, 2006. "Multiple Interfaces of Big Pharma and the Change of Global Health Governance in the Face of HIV/AIDS," GIGA Working Papers 24, GIGA German Institute of Global and Area Studies.
    5. Carrie A. Meyer, 1996. "NGOs and Environmental Public Goods: Institutional Alternatives to Property Rights," Development and Change, International Institute of Social Studies, vol. 27(3), pages 453-474, July.
    6. Razvan Lungeanu & Ithai Stern & Edward J. Zajac, 2016. "When do firms change technology-sourcing vehicles? The role of poor innovative performance and financial slack," Strategic Management Journal, Wiley Blackwell, vol. 37(5), pages 855-869, May.
    7. Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
    8. Abbott, Thomas III, 1995. "Price regulation in the pharmaceutical industry: Prescription or placebo?," Journal of Health Economics, Elsevier, vol. 14(5), pages 551-565, December.
    9. Havas, Attila, 2010. "Diversity in firms’ innovation strategies and activities: Main findings of interviews and implications in the context of the Hungarian national," MPRA Paper 55852, University Library of Munich, Germany.
    10. Unsorg Maximiliane, 2022. "Reference pricing systems on the pharmaceutical market," German Economic Review, De Gruyter, vol. 23(3), pages 403-421, August.
    11. Yoonje Euh & Daeho Lee, 2021. "How Do Pharmaceutical Companies Overcome a Corporate Productivity Crisis? Business Diversification into Medical Devices for Growth Potential," IJERPH, MDPI, vol. 18(3), pages 1-10, January.
    12. Edgardo Barandiarán & Ricardo Paredes, 2002. "Protección de la competencia en Chile: El Estado vs Laboratorios Chile y Recalcine (1992/93)," Working Papers wp191, University of Chile, Department of Economics.
    13. Roger Feldman & Félix Lobo, 2013. "Competition in prescription drug markets: the roles of trademarks, advertising, and generic names," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(4), pages 667-675, August.
    14. Jie Chen & John Rizzo, 2012. "Pricing dynamics and product quality: the case of antidepressant drugs," Empirical Economics, Springer, vol. 42(1), pages 279-300, February.
    15. Richard, Oliver & Van Horn, Larry, 2004. "Persistence in prescriptions of branded drugs," International Journal of Industrial Organization, Elsevier, vol. 22(4), pages 523-540, April.
    16. Nicolas Iung & Frédéric Rupprecht, 1998. "Le marché pharmaceutique français : la prépondérance des produits-phares," Économie et Statistique, Programme National Persée, vol. 312(1), pages 21-33.
    17. Okunade, Albert A. & Murthy, Vasudeva N. R., 2002. "Technology as a 'major driver' of health care costs: a cointegration analysis of the Newhouse conjecture," Journal of Health Economics, Elsevier, vol. 21(1), pages 147-159, January.
    18. Brekke, Kurt R. & Konigbauer, Ingrid & Straume, Odd Rune, 2007. "Reference pricing of pharmaceuticals," Journal of Health Economics, Elsevier, vol. 26(3), pages 613-642, May.
    19. Manning, Richard L, 1997. "Products Liability and Prescription Drug Prices in Canada and the United States," Journal of Law and Economics, University of Chicago Press, vol. 40(1), pages 203-243, April.
    20. Bauner, Christoph & Wang, Emily, 2019. "The effect of competition on pricing and product positioning: Evidence from wholesale club entry," International Journal of Industrial Organization, Elsevier, vol. 67(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:41:y:1997:i:sup1:p:s71-s89. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.